{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T16:56:24Z","timestamp":1777654584601,"version":"3.51.4"},"reference-count":47,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,1,17]],"date-time":"2023-01-17T00:00:00Z","timestamp":1673913600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,1,17]],"date-time":"2023-01-17T00:00:00Z","timestamp":1673913600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Universidad de C\u00f3rdoba"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Langenbecks Arch Surg"],"abstract":"<jats:title>Abstract\n<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Cytoreductive surgery (CRS) with hyperthermic intraperitoneal chemotherapy (HIPEC) causes considerable hemodynamic, respiratory, and metabolic changes during the perioperative period.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Objectives<\/jats:title>\n                <jats:p>To evaluate metabolic changes associated with this procedure. Understanding perioperative factors and their association with morbidity may improve the perioperative management of patients undergoing this treatment.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>A retrospective review of a prospectively maintained database was performed. All consecutive unselected patients who underwent CRS plus HIPEC between January 2018 and December 2020 (<jats:italic>n<\/jats:italic>\u2009=\u2009219) were included.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>The mean age was 58\u2009\u00b1\u200911.7\u00a0years and 167 (76.3%) were female. The most frequent histology diagnosis was serous ovarian carcinoma 49.3% (<jats:italic>n<\/jats:italic>\u2009=\u2009108) and colon carcinoma 36.1% (<jats:italic>n<\/jats:italic>\u2009=\u200979). Mean peritoneal cancer index was 14.07\u2009\u00b1\u200910.47. There were significant variations in pH, lactic acid, sodium, potassium, glycemia, bicarbonate, excess bases, and temperature (<jats:italic>p<\/jats:italic>\u2009&lt;\u20090.05) between the pre-HIPEC and post-HIPEC periods. The closed HIPEC technique resulted in higher levels of temperature than the open technique (<jats:italic>p<\/jats:italic>\u2009&lt;\u20090.05). Age, potassium level post-HIPEC potassium level, and pre-HIPEC glycemia were identified as prognostic factors for morbidity in multivariate analysis.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusion<\/jats:title>\n                <jats:p>The administration of HIPEC after CRS causes significant changes in internal homeostasis. Although the closed technique causes a greater increase in temperature, it is not related to higher morbidity rates. The patient\u2019s age, post-HIPEC potassium level, and pre-HIPEC glycemia are predictive factors for morbidity.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1007\/s00423-023-02770-2","type":"journal-article","created":{"date-parts":[[2023,1,17]],"date-time":"2023-01-17T05:02:45Z","timestamp":1673931765000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Intraoperative metabolic changes associated with cytoreductive surgery and hyperthermic intraperitoneal chemotherapy"],"prefix":"10.1007","volume":"408","author":[{"given":"Jes\u00fas David","family":"Rubio-L\u00f3pez","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Manuel","family":"Dur\u00e1n-Mart\u00ednez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andrea","family":"Moreno-Bl\u00e1zquez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lidia","family":"Rodr\u00edguez-Ortiz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Blanca","family":"Rufi\u00e1n-And\u00fajar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Francisca","family":"Valenzuela-Molina","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"\u00c1ngela Casado","family":"Adam","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Juan M.","family":"S\u00e1nchez-Hidalgo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sebasti\u00e1n","family":"Rufi\u00e1n-Pe\u00f1a","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Antonio","family":"Romero-Ruiz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J","family":"Brice\u00f1o-Delgado","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3024-3009","authenticated-orcid":false,"given":"\u00c1lvaro","family":"Arjona-S\u00e1nchez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2023,1,17]]},"reference":[{"key":"2770_CR1","doi-asserted-by":"publisher","first-page":"358","DOI":"10.1002\/(SICI)1097-0142(20000115)88:2<358::AID-CNCR16>3.0.CO;2-O","volume":"88","author":"B Sadeghi","year":"2000","unstructured":"Sadeghi B, Arvieux C, Glehen O et al (2000) Peritoneal carcinomatosis from non-gynecologic malignancies. results of the EVOCAPE 1 Multicentric Prospective Study. Cancer 88:358\u201363","journal-title":"Cancer"},{"key":"2770_CR2","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1097\/00000658-199501000-00004","volume":"221","author":"PH Sugarbaker","year":"1995","unstructured":"Sugarbaker PH (1995) Peritonectomy procedure. Ann Surg 221:29\u201342","journal-title":"Ann Surg"},{"key":"2770_CR3","first-page":"66","volume":"1","author":"PH Sugarbaker","year":"1988","unstructured":"Sugarbaker PH, Cunliffe W, Belliveau JF, DeBruijn EA, Graves T, Mullins R et al (1988) Rationale for perioperative intraperitoneal chemotherapy as a surgical adjuvant for gastrointestinal malignancy. Reg Cancer Treat 1:66\u201379","journal-title":"Reg Cancer Treat"},{"key":"2770_CR4","first-page":"256","volume":"40","author":"JS Spratt","year":"1980","unstructured":"Spratt JS, Adcock RA, Muskovin M, Sherrill W, McKeown J (1980) Clinical delivery system for intraperitoneal hyperthermic chemotherapy. Cancer Res 40:256\u2013260","journal-title":"Cancer Res"},{"key":"2770_CR5","doi-asserted-by":"publisher","unstructured":"Cochrane Database Syst. Rev. Intraperitoneal chemotherapy for the initial management of primary epithelial ovarian cancer. Cochrane Database Syst Rev (11): CD005340. https:\/\/doi.org\/10.1002\/14651858.CD005340.pub3.","DOI":"10.1002\/14651858.CD005340.pub3"},{"issue":"6","key":"2770_CR6","doi-asserted-by":"publisher","first-page":"1263","DOI":"10.1007\/s00268-013-2000-2","volume":"37","author":"A Arjona-Sanchez","year":"2013","unstructured":"Arjona-Sanchez A, Mu\u00f1oz-Casares FC, Casado-Adam A et al (2013) Outcome of patients with aggressive pseudomyxomaperitonei treated by cytoreductive surgery and intraperitoneal chemotherapy. World J Surg 37(6):1263\u20131270","journal-title":"World J Surg"},{"key":"2770_CR7","doi-asserted-by":"publisher","first-page":"224","DOI":"10.1016\/j.ejso.2015.11.006","volume":"42","author":"C Mu\u00f1oz-Casares","year":"2016","unstructured":"Mu\u00f1oz-Casares C, Medina-Fern\u00e1ndez FJ, Arjona-S\u00e1nchez A et al (2016) Peritonectomy procedures and HIPEC in the treatment of peritoneal carcinomatosis from ovarian cancer: long-term outcomes and perspectives from a high-volume center. EJSO 42:224\u2013233","journal-title":"EJSO"},{"key":"2770_CR8","doi-asserted-by":"publisher","first-page":"1570","DOI":"10.1245\/s10434-014-4157-9","volume":"22","author":"J Spiliotis","year":"2015","unstructured":"Spiliotis J, Halkia E, Lianos E et al (2015) Cytoreductive surgery and HIPEC in recurrent epithelial ovarian cancer: a prospective randomized phase III study. Ann Surg Oncol 22:1570\u20131575","journal-title":"Ann Surg Oncol"},{"key":"2770_CR9","doi-asserted-by":"publisher","first-page":"CD005340","DOI":"10.1002\/14651858.CD005340.pub4","volume":"1","author":"K Jaaback","year":"2016","unstructured":"Jaaback K, Johnson N, Lawrie TA (2016) Intraperitoneal chemotherapy for the initial management of primary epithelial ovarian cancer (review). Cochrane Database Syst Rev 1:CD005340. https:\/\/doi.org\/10.1002\/14651858.CD005340.pub4","journal-title":"Cochrane Database Syst Rev"},{"key":"2770_CR10","doi-asserted-by":"publisher","first-page":"484","DOI":"10.1245\/s10434-006-9182-x","volume":"14","author":"TD Yan","year":"2007","unstructured":"Yan TD, Black D, Savady R, Sugarbaker PH (2007) A systematic review on the efficacy of cytoreductive surgery and perioperative intraperitoneal chemotherapy for pseudomixoma peritonei. Ann Surg Oncol 14:484\u2013492","journal-title":"Ann Surg Oncol"},{"key":"2770_CR11","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1200\/JCO.2003.04.187","volume":"21","author":"VJ Verwaal","year":"2003","unstructured":"Verwaal VJ, van Ruth S, de Bree E et al (2003) Randomized trial of cytoreduction and hyperthermic intraperitoneal chemotherapy versus systemic chemotherapy and palliative surgery in patients with peritoneal carcinomatosis of colorectal cancer. J Clin Oncol 21:37\u201343","journal-title":"J Clin Oncol"},{"key":"2770_CR12","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1200\/JCO.2009.23.9285","volume":"28","author":"D Elias","year":"2010","unstructured":"Elias D, Gilly F, Boutitie F et al (2010) Peritoneal colorectal carcinomatosis treated with surgery and perioperative intraperitoneal chemotherapy: retrospective analysis of 523 patients from a multicentric French study. J Clin Oncol 28:63\u201368","journal-title":"J Clin Oncol"},{"key":"2770_CR13","doi-asserted-by":"publisher","first-page":"827","DOI":"10.1093\/annonc\/mdl428","volume":"18","author":"TD Yan","year":"2007","unstructured":"Yan TD, Welch L, Black D, Sugarbaker PH (2007) A systematic review on the efficacy of cytorreductive surgery and perioperative intraperitoneal chemotherapy for diffuse malignancy peritoneal mesothelioma. Ann Oncol 18:827\u2013834","journal-title":"Ann Oncol"},{"issue":"1","key":"2770_CR14","doi-asserted-by":"publisher","first-page":"138","DOI":"10.1097\/SLA.0b013e3182193143","volume":"254","author":"N Piche","year":"2011","unstructured":"Piche N, Leblond FA, Sideris L et al (2011) Rationale for heating oxaliplatin for the intraperitoneal treatment of peritoneal carcinomatosis: a study of the effect of heat on intraperitoneal oxaliplatin using a murine model. Ann Surg 254(1):138\u2013144","journal-title":"Ann Surg"},{"key":"2770_CR15","doi-asserted-by":"publisher","first-page":"900","DOI":"10.1097\/SLA.0b013e3181a45d86","volume":"249","author":"C Chua","year":"2009","unstructured":"Chua C, Yan D, Saxena A, Morris D (2009) Should the treatment of peritoneal carcinomatosis by cytoreductive surgery and hyperthermic intraperitoneal chemotherapy still be regarded as a highly morbid procedure? A systematic review of morbidity and primarily. Ann Surg 249:900\u2013907","journal-title":"Ann Surg"},{"issue":"1","key":"2770_CR16","doi-asserted-by":"publisher","first-page":"e186847","DOI":"10.1001\/jamanetworkopen.2018.6847","volume":"2","author":"JM Foster","year":"2019","unstructured":"Foster JM, Sleightholm R, Patel A et al (2019) Morbidity and mortality rates following cytoreductive surgery combined with hyperthermic intraperitoneal chemotherapy compared with other high-risk surgical oncology procedures. JAMA Netw Open 2(1):e186847. https:\/\/doi.org\/10.1001\/jamanetworkopen.2018.6847","journal-title":"JAMA Netw Open"},{"key":"2770_CR17","first-page":"3","volume":"25","author":"C Raspe","year":"2012","unstructured":"Raspe C, Piso P, Wiesenack C, Bucher M (2012) Anesthetic management in patients undergoing hyperthermic chemotherapy. Anesth med dis 25:3","journal-title":"Anesth med dis"},{"issue":"10","key":"2770_CR18","doi-asserted-by":"publisher","first-page":"676","DOI":"10.1016\/j.annfar.2010.06.021","volume":"29","author":"J Raft","year":"2010","unstructured":"Raft J, Parisot M, Marchal F et al (2010) Impact of the hyperthermic intraperitoneal chemotherapy on the fluid-electrolytes changes and on the acid-base balance. Ann Fr Anesth Reanim 29(10):676\u201381. https:\/\/doi.org\/10.1016\/j.annfar.2010.06.021","journal-title":"Ann Fr Anesth Reanim"},{"key":"2770_CR19","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1177\/089686080802800111","volume":"28","author":"F De Somer","year":"2008","unstructured":"De Somer F, Ceelen W, Delanghe J et al (2008) Severe hyponatremia, hyperglycemia, and hyperlactatemia are associated with intraoperative hyperthermic intraperitoneal chemoperfusion with oxaliplatin. Perit Dial Int 28:61\u201366","journal-title":"Perit Dial Int"},{"key":"2770_CR20","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1177\/089686080802800107","volume":"28","author":"MK Nguyen","year":"2008","unstructured":"Nguyen MK (2008) Lessons learned from hyponatremia associated with hyperthermic intraperitoneal chemoperfusion with oxaliplatin. Perit Dial Int 28:32\u201334","journal-title":"Perit Dial Int"},{"issue":"2","key":"2770_CR21","doi-asserted-by":"publisher","first-page":"535","DOI":"10.1245\/s10434-007-9648-5","volume":"15","author":"WP Ceelen","year":"2008","unstructured":"Ceelen WP, Peeters M, Houtmeyers P, Breusegem C et al (2008) Safety and efficacy of hyperthermic intraperitoneal chemoperfusion with oxaliplatin in patients with peritoneal carcinomatosis. Ann Surg Oncol 15(2):535\u201341","journal-title":"Ann Surg Oncol"},{"key":"2770_CR22","doi-asserted-by":"publisher","first-page":"869","DOI":"10.1016\/j.ejso.2015.12.016","volume":"42","author":"\u00c1 Arjona-S\u00e1nchez","year":"2016","unstructured":"Arjona-S\u00e1nchez \u00c1, Cadenas-Febres A, Cabrera-Bermon J et al (2016) Assessment of RIFLE and AKIN criteria to define acute renal dysfunction for HIPEC procedures for ovarian and non ovarian peritoneal malignances. EJSO 42:869\u2013876","journal-title":"EJSO"},{"key":"2770_CR23","first-page":"49","volume":"15","author":"P Jaquet","year":"1996","unstructured":"Jaquet P, Sugarbaker PH (1996) Current methodologies for clinical assessment of patients with peritoneal carcinomatosis. J ExpClin Cancer Res 15:49\u201358","journal-title":"J ExpClin Cancer Res"},{"issue":"5","key":"2770_CR24","doi-asserted-by":"publisher","first-page":"488","DOI":"10.3109\/02656736.2016.1152515","volume":"32","author":"S S\u00e1nchez-Garc\u00eda","year":"2016","unstructured":"S\u00e1nchez-Garc\u00eda S, Villarejo-Campos P, Padilla-Valverde D, Amo-Salas M, Mart\u00edn-Fern\u00e1ndez J (2016) Intraperitoneal chemotherapy hyperthermia (HIPEC) for peritoneal carcinomatosis of ovarian cancer origin by fluid and CO2 recirculation using the closed abdomen technique (PRS-1.0 Combat): a clinical pilot study. Int J Hyperthermia 32(5):488\u201395","journal-title":"Int J Hyperthermia."},{"key":"2770_CR25","doi-asserted-by":"publisher","first-page":"825","DOI":"10.1097\/ALN.0000000000002603","volume":"130","author":"TE Miller","year":"2019","unstructured":"Miller TE, Myles PS (2019) Perioperative fluid therapy for major surgery. Anesthesiol 130:825\u2013832","journal-title":"Anesthesiol"},{"key":"2770_CR26","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1001\/jamanetworkopen.2018.6847","volume":"2","author":"RL Harmon","year":"2005","unstructured":"Harmon RL, Sugarbaker PH (2005) Prognostic indicators in peritoneal carcinomatosis from gastrointestinal cancer. Int Semin Surg Oncol 2:3. https:\/\/doi.org\/10.1001\/jamanetworkopen.2018.6847","journal-title":"Int Semin Surg Oncol"},{"key":"2770_CR27","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1097\/SLA.0b013e3181b13ca2","volume":"250","author":"PA Clavien","year":"2009","unstructured":"Clavien PA, Barkun J, de Oliveira ML et al (2009) The Clavien-Dindo classification of surgical complications: five-year experience. Ann Surg 250:187\u2013196","journal-title":"Ann Surg"},{"key":"2770_CR28","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1097\/01.sla.0000133083.54934.ae","volume":"240","author":"D Dindo","year":"2004","unstructured":"Dindo D, Demartines N, Clavien PA (2004) Classification of surgical complications: a new proposal with evaluation in a cohort of 6336 patients and results of a survey. Ann Surg 240:205\u2013213","journal-title":"Ann Surg"},{"issue":"4","key":"2770_CR29","doi-asserted-by":"publisher","first-page":"533","DOI":"10.1016\/j.soc.2012.07.003","volume":"21","author":"KP Rothfield","year":"2012","unstructured":"Rothfield KP, Crowley K (2012) Anesthesia considerations during cytoreductive surgery and hyperthermic intraperitoneal chemotherapy. Surg Oncol Clin N Am 21(4):533\u2013541","journal-title":"Surg Oncol Clin N Am"},{"key":"2770_CR30","first-page":"414","volume":"98","author":"PH Sugarbaker","year":"1985","unstructured":"Sugarbaker PH, Gianola FJ, Speyer JC et al (1985) Prospective, randomized trial of intravenous versus intraperitoneal 5-fluorouracil in patients with advanced primary colon or rectal cancer. Surg 98:414\u2013422","journal-title":"Surg"},{"issue":"1","key":"2770_CR31","doi-asserted-by":"publisher","first-page":"222","DOI":"10.1245\/s10434-019-07518-1","volume":"27","author":"NL Leigh","year":"2020","unstructured":"Leigh NL, Solomon D, Feingold D et al (2020) Improved survival with experience: a 10-year learning curve in hyperthermic intraperitoneal chemotherapy and cytoreductive surgery. Ann Surg Oncol 27(1):222\u2013231","journal-title":"Ann Surg Oncol"},{"issue":"3","key":"2770_CR32","doi-asserted-by":"publisher","first-page":"267","DOI":"10.1097\/MCC.0b013e3283532b8a","volume":"18","author":"BM Fuller","year":"2012","unstructured":"Fuller BM, Dellinger RP (2012) Lactate as a hemodynamic marker in the critically ill. Curr Opin Crit Care 18(3):267\u2013272","journal-title":"Curr Opin Crit Care"},{"issue":"2 Pt A","key":"2770_CR33","doi-asserted-by":"publisher","first-page":"156","DOI":"10.1016\/j.canlet.2014.04.001","volume":"356","author":"J Lu","year":"2015","unstructured":"Lu J, Tan M, Cai Q (2015) The Warburg effect in tumor progression: mitochondrial oxidative metabolism as an anti-metastasis mechanism. Cancer Lett 356(2 Pt A):156\u2013164","journal-title":"Cancer Lett"},{"issue":"8","key":"2770_CR34","doi-asserted-by":"crossref","first-page":"E1036","DOI":"10.1152\/ajpendo.00151.2012","volume":"303","author":"CA Aneba","year":"2021","unstructured":"Aneba CA, Bellance N, Yang L, Pabst L, Nagrath D (2021) Pyruvate uptake is increased in highly invasive ovarian cancer cells under anoikis conditions for anaplerosis, mitochondrial function, and migration. Am J Physiol Endocrinol Metab 303(8):E1036\u2013E1052","journal-title":"Am J Physiol Endocrinol Metab"},{"key":"2770_CR35","doi-asserted-by":"crossref","unstructured":"Tonello M, Barina A, Turchet F et al (2020) Clinical and predictive value of blood lactate levels during cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (HIPEC): a comparative analysis. Updates Surg 2021 Feb 73(1):313\u2013319","DOI":"10.1007\/s13304-020-00908-1"},{"issue":"2","key":"2770_CR36","doi-asserted-by":"publisher","first-page":"334","DOI":"10.1245\/s10434-008-0253-z","volume":"16","author":"N Miao","year":"2009","unstructured":"Miao N, Pingpank JF, Alexander HR, Royal R, Steinberg SM, Quezado MM et al (2009) Cytoreductive surgery and continuous hyperthermic. Peritoneal perfusion in patients with mesothelioma and peritoneal carcinomatosis: hemodynamic, metabolic and anesthetic considerations. Ann Surg Oncol 16(2):334\u201344","journal-title":"Ann Surg Oncol"},{"key":"2770_CR37","doi-asserted-by":"publisher","first-page":"174","DOI":"10.1245\/s10434-010-1210-1","volume":"18","author":"NM Rueth","year":"2011","unstructured":"Rueth NM, Murray SE, Huddleston SJ et al (2011) Severe electrolyte disturbances after hyperthermic intraperitoneal chemotherapy: oxaliplatin versus mitomycin C. Ann Surg Oncol 18:174\u2013180","journal-title":"Ann Surg Oncol"},{"key":"2770_CR38","doi-asserted-by":"publisher","first-page":"676","DOI":"10.1016\/j.annfar.2010.06.021","volume":"29","author":"J Raft","year":"2010","unstructured":"Raft J et al (2010) Impact of the hyperthermic intraperitoneal chemotherapy on the fluid-electrolyte changes and on the acid-base balance. Annales Francaises d\u2019Anesthesie et de R\u00e9animation 29:676\u2013681","journal-title":"Annales Francaises d\u2019Anesthesie et de R\u00e9animation"},{"key":"2770_CR39","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1177\/089686080802800111","volume":"28","author":"F De Somer","year":"2008","unstructured":"De Somer F, Ceelen W, Delanghe J, De Smet D, Vanackere M, Pattyn P et al (2008) Severe hyponatremia, hyperglycemia, and hy- hyperlactatemia are associated with intraoperative hyperthermic intraperitoneal chemoperfusion with oxaliplatin. Perit Dial Int 28:61\u201366","journal-title":"Perit Dial Int"},{"key":"2770_CR40","doi-asserted-by":"publisher","first-page":"376","DOI":"10.1007\/s004649900993","volume":"13","author":"SP Dexter","year":"1999","unstructured":"Dexter SP, Vucevic M, Gibson J, McMahon MJ (1999) Hemodynamic consequences of high- and low- pressure capnoperitoneum during laparoscopic cholecystectomy. Surg Endosc 13:376\u2013381","journal-title":"Surg Endosc"},{"key":"2770_CR41","doi-asserted-by":"publisher","first-page":"389","DOI":"10.1111\/j.1365-2044.2007.05380.x","volume":"63","author":"C Schmidt","year":"2008","unstructured":"Schmidt C, Creutzenberg M (2008) Peri-operative anesthetic management of cytoreductive surgery with hyperthermic intraperitoneal chemotherapy. Anesthesia 63:389\u2013395","journal-title":"Anesthesia"},{"key":"2770_CR42","doi-asserted-by":"publisher","first-page":"687","DOI":"10.1007\/s00104-018-0677-3","volume":"89","author":"D Bleiler","year":"2018","unstructured":"Bleiler D, Bleiler S, Sinner B (2018) Perioperatives Management im Rahmen der CRS und HIPEC. Chirurg 89:687\u2013692","journal-title":"Chirurg"},{"key":"2770_CR43","doi-asserted-by":"publisher","first-page":"P200","DOI":"10.1186\/cc573","volume":"3","author":"A Nierhaus","year":"2000","unstructured":"Nierhaus A, Meissner C, Hegewisch S et al (2000) Alterations of metabolic and hemodynamic parameters during whole body hyperthermia on the ICU. Crit Care 3:P200","journal-title":"Crit Care"},{"key":"2770_CR44","doi-asserted-by":"publisher","first-page":"303","DOI":"10.1186\/s13054-016-1467-2","volume":"20","author":"JF Doyle","year":"2016","unstructured":"Doyle JF, Schortgen F (2016) Should we treat pyrexia? And how do we do it? Crit Care 20:303","journal-title":"Crit Care"},{"issue":"20","key":"2770_CR45","doi-asserted-by":"publisher","first-page":"2449","DOI":"10.1200\/JCO.2011.39.7166","volume":"30","author":"TC Chua","year":"2012","unstructured":"Chua TC, Moran BJ, Sugarbaker PH et al (2012) Early and long-term outcome data of patients with Pseudomyxoma peritonei from appendiceal origin treated by a strategy of cytoreductive surgery and hyperthermic intraperitoneal chemotherapy. J Clin Oncol< 30(20):2449\u20132456","journal-title":"J Clin Oncol<"},{"key":"2770_CR46","doi-asserted-by":"publisher","first-page":"456","DOI":"10.1016\/j.ejso.2010.01.006","volume":"36","author":"D Elias","year":"2010","unstructured":"Elias D, Gilly F, Quenet F et al (2010) Pseudomyxoma peritonei: a French multicentric study of 301 patients treated with cytoreductive surgery and intraperitoneal chemotherapy. Eur J Surg Oncol 36:456\u2013462","journal-title":"Eur J Surg Oncol"},{"key":"2770_CR47","doi-asserted-by":"crossref","unstructured":"Baumgartner JM, Kwong TG et al (2015) A novel tool for predicting major complications after cytoreductive surgery with hyperthermic intraperitoneal chemotherapy. Ann Surg Oncol 2016 May 23(5):1609\u201317","DOI":"10.1245\/s10434-015-5012-3"}],"updated-by":[{"DOI":"10.1007\/s00423-023-02824-5","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2023,2,16]],"date-time":"2023-02-16T00:00:00Z","timestamp":1676505600000}}],"container-title":["Langenbeck's Archives of Surgery"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00423-023-02770-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00423-023-02770-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00423-023-02770-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,1,18]],"date-time":"2024-01-18T18:03:44Z","timestamp":1705601024000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00423-023-02770-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,1,17]]},"references-count":47,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,12]]}},"alternative-id":["2770"],"URL":"https:\/\/doi.org\/10.1007\/s00423-023-02770-2","relation":{"correction":[{"id-type":"doi","id":"10.1007\/s00423-023-02824-5","asserted-by":"object"}]},"ISSN":["1435-2451"],"issn-type":[{"value":"1435-2451","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,1,17]]},"assertion":[{"value":"8 March 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 December 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 January 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 February 2023","order":4,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Correction","order":5,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"A Correction to this paper has been published:","order":6,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"https:\/\/doi.org\/10.1007\/s00423-023-02824-5","URL":"https:\/\/doi.org\/10.1007\/s00423-023-02824-5","order":7,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"34"}}